Table 4.

Total deviation of viscosity at 150 and 175 mg/ml for eight IgG4P mAbs (ganitumab, trastuzumab (Herceptin®), Adalimumab, golimumab, basiliximab, TGN1412, tremelimumab, and ipilimumab) as a function of ${\mathrm{A}}_{\mathrm{H}}^{\mathrm{c}}$ and chgCH3. The deviation for each IgG4P mAb is defined as ${\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}4}^{\mathrm{C}\mathrm{G}}-{\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}4}^{\mathrm{e}\mathrm{x}\mathrm{p}}-\left({\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}1}^{\mathrm{C}\mathrm{G}}-{\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}1}^{\mathrm{e}\mathrm{x}\mathrm{p}}\right)$. The deviation is offset by the viscosity difference between experiment and computation of IgG1 mAbs to account for the effect of variable regions on the viscosity. The total deviation is defined as $\sum \left|{\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}4}^{\mathrm{C}\mathrm{G}}-{\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}4}^{\mathrm{e}\mathrm{x}\mathrm{p}}-\left({\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}1}^{\mathrm{C}\mathrm{G}}-{\mathrm{V}\mathrm{i}\mathrm{s}}_{\mathrm{G}1}^{\mathrm{e}\mathrm{x}\mathrm{p}}\right)\right|$

Total deviation (cP)		(kcal/mol)
		0.12	0.14	0.16	0.18
chgCH3 (e)	−0.2	180.8	183.4	183.5	181
	−0.4	164.5	166.5	165.3	165.1
	−0.6	163.1	160.8	160	163.6
	−0.8	153.3	154.9	164.6	184.4